Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LB8Z
|
|||
| Drug Name |
TPIV200
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1], [2] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1], [2], [3], [4] | ||
| Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [3] | ||
| Company |
Andarix Pharmaceuticals Somerville, NJ, Jacksonville, FL
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.